SCHEMBL4091785

SCHEMBL4091785

CC1CCC(C(NC(=O)Nc2ccc(Oc3ccccc3)cc2)c2ccc(C(=O)NCCC(=O)O)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.49
GCGR P47871 7/20 0.47
ADCY6 O43306 3/20 0.47
ADCY3 O60266 3/20 0.47
ADCY9 O60503 3/20 0.47
ADCY5 O95622 3/20 0.47
ADCY8 P40145 3/20 0.47
ADCY7 P51828 3/20 0.47
ADCY2 Q08462 3/20 0.47
ADCY1 Q08828 3/20 0.47
ADCY4 Q8NFM4 3/20 0.47
MCHR2 Q969V1 2/20 0.46
F2 P00734 2/20 0.43
F7 P08709 2/20 0.43
GCG P01275 2/20 0.42
NPY5R Q15761 1/20 0.42
PGR P06401 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091187 0.91 GCGR (0.53) MCHR1GCGRADCY6ADCY3ADCY9
SCHEMBL4091754 0.90 MCHR1 (0.47) MCHR1GCGRADCY6ADCY3ADCY9
SCHEMBL4081585 0.88 GCGR (0.57) MCHR1GCGRADCY6ADCY3ADCY9
SCHEMBL4087094 0.86 MCHR1 (0.48) MCHR1GCGRADCY6ADCY3ADCY9
SCHEMBL2650947 0.82 F2 (0.44) MCHR1GCGRF2F7GCG
SCHEMBL4087196 0.82 GCGR (0.58) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4087190 0.82 GCGR (0.58) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4081393 0.82 GCGR (0.64) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4086773 0.82 GCGR (0.53) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4087498 0.81 GCGR (0.66) MCHR1GCGRADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR MCHR1 178/4885GCGR 3/4885ADCY6 956/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MCHR1 178/4885GCGR 3/4885ADCY6 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.